Portfolio company
Ellis Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops bisulfite conversion kits for DNA methylation analysis, serving clinical and academic researchers in the epigenomics and oncology sectors.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Epigenica
This company develops epigenetic analysis kits and screening tools for researchers in drug discovery, diagnostics, and precision medicine.
Epiliquid
This company develops blood-based liquid biopsy tests for early cancer detection and monitoring, serving clinical laboratories and medical practitioners.
Auristone
This company develops epigenomic profiling tools and bioinformatics services for clinicians and researchers to support precision medicine and cancer drug discovery.
Syndex Bio
This company develops a polymerase chain reaction platform that amplifies DNA methylation patterns for clinicians and researchers involved in early disease detection.
BioSkryb
This company develops genomic amplification and sequencing systems for researchers and clinicians to analyse DNA and RNA from single cells.
Biomodal
This company develops multiomics sequencing kits and software for life scientists and clinical developers to analyse genetic and epigenetic data from single DNA samples.
Precede Biosciences
The company develops an epigenomic liquid biopsy platform for biopharmaceutical companies and researchers to profile gene expression and disease biology from blood samples.
Cispoly
This company develops methylation detection kits for the early diagnosis of gynaecological cancers for healthcare providers and public health initiatives.
